• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于无偏相关性检验的新型方法,用于非线性混合效应模型中的协变量选择:COSSAC 方法。

A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach.

机构信息

Lixoft, Antony, France.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):318-329. doi: 10.1002/psp4.12612.

DOI:10.1002/psp4.12612
PMID:33755345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8099437/
Abstract

Building a covariate model is a crucial task in population pharmacokinetics and pharmacodynamics in order to understand the determinants of the interindividual variability. Identifying a good covariate model usually requires many runs. Several procedures have been proposed in the past to automatize this task. The most commonly used is Stepwise Covariate Modeling (SCM). Here, we present a novel stepwise method based on statistical tests between individual parameters sampled from their conditional distribution and the covariates. This strategy, called the COnditional Sampling use for Stepwise Approach based on Correlation tests (COSSAC), makes use of the information contained in the current model to choose which parameter-covariate relationship to try next. This strategy greatly reduces the number of covariate models tested, while retaining on its search path the models improving the log-likelihood (LL). In this article, we detail the COSSAC method and its implementation in Monolix, and evaluate its performance. The performance was assessed by comparing COSSAC to the traditional SCM method on 17 representative data sets. For the large majority of cases (15 out of 17), the final covariate model is identical (11 cases) or very similar (4 cases with LL differences less than 3.84) with both procedures. Yet, COSSAC requires between 2 to 20 times fewer runs than SCM. This represents a decisive speed up, especially for models that take long to run and would not be tractable using the SCM method.

摘要

建立协变量模型是群体药代动力学和药效学中的一项关键任务,以便了解个体间变异性的决定因素。确定一个好的协变量模型通常需要多次运行。过去已经提出了几种程序来自动化这项任务。最常用的方法是逐步协变量建模(SCM)。在这里,我们提出了一种新的基于从条件分布中抽样的个体参数与协变量之间的统计检验的逐步方法。这种策略称为基于相关性检验的条件抽样逐步方法(COSSAC),它利用当前模型中包含的信息来选择要尝试的下一个参数-协变量关系。该策略大大减少了测试的协变量模型的数量,同时保留了对提高对数似然度(LL)有帮助的模型。在本文中,我们详细介绍了 COSSAC 方法及其在 Monolix 中的实现,并评估了其性能。通过将 COSSAC 与传统的 SCM 方法在 17 个有代表性的数据集上进行比较,评估了其性能。对于绝大多数情况(17 个案例中的 15 个),最终的协变量模型与两种方法完全相同(11 个案例)或非常相似(4 个案例的 LL 差异小于 3.84)。然而,COSSAC 所需的运行次数比 SCM 少 2 到 20 倍。这代表了一个决定性的加速,特别是对于那些运行时间长且使用 SCM 方法不可行的模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/9f036acf7c65/PSP4-10-318-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/dbc98f9a9f07/PSP4-10-318-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/5dce57ccfc2a/PSP4-10-318-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/9f036acf7c65/PSP4-10-318-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/dbc98f9a9f07/PSP4-10-318-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/5dce57ccfc2a/PSP4-10-318-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6930/8099437/9f036acf7c65/PSP4-10-318-g003.jpg

相似文献

1
A novel method based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach.一种基于无偏相关性检验的新型方法,用于非线性混合效应模型中的协变量选择:COSSAC 方法。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):318-329. doi: 10.1002/psp4.12612.
2
SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models.SAMBA:一种新的非线性混合效应模型中快速自动模型构建的方法。
CPT Pharmacometrics Syst Pharmacol. 2022 Feb;11(2):161-172. doi: 10.1002/psp4.12742. Epub 2022 Feb 1.
3
The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models.套索法——一种用于非线性混合效应模型中预测协变量模型构建的新方法。
J Pharmacokinet Pharmacodyn. 2007 Aug;34(4):485-517. doi: 10.1007/s10928-007-9057-1. Epub 2007 May 22.
4
Fast screening of covariates in population models empowered by machine learning.基于机器学习的群体模型中协变量的快速筛选。
J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):597-609. doi: 10.1007/s10928-021-09757-w. Epub 2021 May 21.
5
A Modified Hybrid Wald's Approximation Method for Efficient Covariate Selection in Population Pharmacokinetic Analysis.改良的混合 Wald 近似法在群体药代动力学分析中高效进行协变量选择。
AAPS J. 2021 Mar 3;23(2):37. doi: 10.1208/s12248-021-00572-2.
6
Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.增强型药代动力学模型诊断方法:条件分布的随机抽样。
Pharm Res. 2016 Dec;33(12):2979-2988. doi: 10.1007/s11095-016-2020-3. Epub 2016 Sep 7.
7
An Evolutionary Search Algorithm for Covariate Models in Population Pharmacokinetic Analysis.群体药代动力学分析中协变量模型的一种进化搜索算法。
J Pharm Sci. 2017 Sep;106(9):2407-2411. doi: 10.1016/j.xphs.2017.04.029. Epub 2017 Apr 25.
8
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.临床无关标准在协变量模型构建中的应用及在多非利特药代动力学数据中的应用
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):503-26. doi: 10.1007/s10928-008-9099-z. Epub 2008 Nov 15.
9
Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.用于非线性混合效应药代动力学模型中协变量模型构建的调整自适应套索法
J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):55-66. doi: 10.1007/s10928-017-9504-6. Epub 2017 Jan 31.
10
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.应用单目标混合遗传算法方法进行药代动力学模型构建。
J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):393-414. doi: 10.1007/s10928-012-9258-0. Epub 2012 Jul 6.

引用本文的文献

1
Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab.群体药代动力学/药效学分析证实SB16与参比地诺单抗具有生物相似性。
Front Pharmacol. 2025 Aug 19;16:1631034. doi: 10.3389/fphar.2025.1631034. eCollection 2025.
2
Shap-Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling.Shap-Cov:一种基于可解释机器学习的工作流程,用于在人群建模中快速识别协变量。
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1322-1331. doi: 10.1002/psp4.70044. Epub 2025 Jul 2.
3
Do Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Require Ceftaroline Dosage Adjustments? Ceftaroline PopPK Model and Dosage Simulations with the Probability of Target Attainment Analysis Based on Retrospective Data.

本文引用的文献

1
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.连续数据药代动力学模型的模型评估:指标与图形
CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):87-109. doi: 10.1002/psp4.12161. Epub 2017 Feb 10.
2
Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.增强型药代动力学模型诊断方法:条件分布的随机抽样。
Pharm Res. 2016 Dec;33(12):2979-2988. doi: 10.1007/s11095-016-2020-3. Epub 2016 Sep 7.
3
Covariate selection in pharmacometric analyses: a review of methods.
接受持续肾脏替代治疗的重症患者是否需要调整头孢洛林剂量?基于回顾性数据的头孢洛林群体药代动力学模型及剂量模拟与目标达成概率分析
Antibiotics (Basel). 2025 Mar 27;14(4):347. doi: 10.3390/antibiotics14040347.
4
A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.一种用于表征莫努匹拉韦对感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)门诊患者抗病毒作用的病毒免疫学模型:对治疗持续时间的启示。
J Infect Dis. 2025 Jul 11;231(6):e1080-e1090. doi: 10.1093/infdis/jiaf158.
5
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.一种HIV广泛中和单克隆抗体VRC07-523LS的药代动力学相互作用评估:对三项针对未感染HIV人群的1期试验的跨方案分析
BMC Immunol. 2025 Feb 19;26(1):8. doi: 10.1186/s12865-025-00687-7.
6
Pharmacokinetic modeling of prenatal vitamin D exposure and the impact on offspring asthma and pulmonary function.产前维生素D暴露的药代动力学建模及其对后代哮喘和肺功能的影响。
Biomed Pharmacother. 2025 Feb;183:117859. doi: 10.1016/j.biopha.2025.117859. Epub 2025 Jan 27.
7
Covariate Model Selection Approaches for Population Pharmacokinetics: A Systematic Review of Existing Methods, From SCM to AI.群体药代动力学的协变量模型选择方法:从结构方程模型到人工智能的现有方法系统综述
CPT Pharmacometrics Syst Pharmacol. 2025 Apr;14(4):621-639. doi: 10.1002/psp4.13306. Epub 2025 Jan 20.
8
Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study.NX210c肽在健康老年志愿者中的安全性、耐受性及药代动力学-药效学关系:随机、安慰剂对照、双盲、多次递增剂量研究
Neurol Ther. 2025 Feb;14(1):357-377. doi: 10.1007/s40120-024-00691-w. Epub 2024 Dec 21.
9
Isatuximab-dexamethasone-pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data.isatuximab-地塞米松-泊马度胺联合用药对骨髓瘤患者血清M蛋白及无进展生存期的影响:利用I/II期数据建立联合模型
CPT Pharmacometrics Syst Pharmacol. 2024 Dec;13(12):2087-2101. doi: 10.1002/psp4.13206. Epub 2024 Nov 28.
10
Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice.在临床实践中,将群体药代动力学建模与精准给药相结合的推荐方法。
Br J Clin Pharmacol. 2025 Apr;91(4):1064-1079. doi: 10.1111/bcp.16335. Epub 2024 Nov 21.
药代动力学分析中的协变量选择:方法综述
Br J Clin Pharmacol. 2015 Jan;79(1):132-47. doi: 10.1111/bcp.12451.
4
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.群体建模、模拟及基于模型的药物研发基础概念——第2部分:药代动力学建模方法介绍
CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17;2(4):e38. doi: 10.1038/psp.2013.14.
5
The lasso--a novel method for predictive covariate model building in nonlinear mixed effects models.套索法——一种用于非线性混合效应模型中预测协变量模型构建的新方法。
J Pharmacokinet Pharmacodyn. 2007 Aug;34(4):485-517. doi: 10.1007/s10928-007-9057-1. Epub 2007 May 22.
6
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.PsN工具包——一组使用NONMEM进行非线性混合效应建模的计算机密集型统计方法。
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57. doi: 10.1016/j.cmpb.2005.04.005.
7
Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.群体药代动力学协变量模型的效能、选择偏倚及预测性能
J Pharmacokinet Pharmacodyn. 2004 Apr;31(2):109-34. doi: 10.1023/b:jopa.0000034404.86036.72.
8
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.群体药代动力学-药效学分析中逐步协变量模型构建策略的比较
AAPS PharmSci. 2002;4(4):E27. doi: 10.1208/ps040427.
9
Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose.香豆素类抗凝药物的研究。不采用负荷剂量起始华法林治疗。
Circulation. 1968 Jul;38(1):169-77. doi: 10.1161/01.cir.38.1.169.
10
Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.使用似然比检验的Wald近似法在总体模型中有效筛选协变量。
J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):253-75. doi: 10.1023/a:1011579109640.